Skip to content
‹ Back to IndustriesHealthcare

Should the COVID-19 Vaccine’s Intellectual Property Be Accessible for Everyone?

Key Words: Intellectual property protection is important because you have rogue scientists and organizations who might try and do a knock off of the vaccine that isn’t the same quality, which could be dangerous because it isn’t as effective. Pharmaceutical companies shouldn’t be making profit off of drugs that treat neglected diseases. Accessibility of…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

·
Share

Free workspace

Turn your Healthcare expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

Key Words:

  • Intellectual property protection is important because you have rogue scientists and organizations who might try and do a knock off of the vaccine that isn’t the same quality, which could be dangerous because it isn’t as effective.
  • Pharmaceutical companies shouldn’t be making profit off of drugs that treat neglected diseases.
  • Accessibility of the COVID-19 vaccine such as the inability to properly store the vaccine, is one of the biggest problems for certain parts of the world when it comes to vaccine distribution.

Commentary:

Although the COVID-19 vaccine is readily available, it isn’t necessarily available for everyone. Some countries across the globe do not have access to the vaccine partially because of intellectual property claims. Intellectual properties protect the patents of drugs like the COVID-19 vaccine, making it so that the information on how to make it, is only shared with a select group of people. Right now there is a battle over whether or not countries like the United States should share the IP of the COVID-19 vaccine. MarketScale reached out to Dr. Kishor Wasan about this topic and we asked his opinion on the World Trade Organization and TRIPS Council’s decision to lean so heavily on protecting IPs rather than what some may argue is looking out for the global good by making the COVID-19 vaccine more accessible.

Abridged Thoughts:

So intellectual property is partly there because yes, it’s there so they can make money and protect their invention. But at the same time, it’s also there so that, the product is protected, so that people don’t do rogue products and make a substandard version of it. That’s why this is actually a very controversial and tricky issue. It’s not that black and white. I mean, it’s not as simple as that. So you have to kind of keep those two things in mind. And again, it comes down to a balance between the two.

Medical Professionals Leave and Join the Industry in Droves. How Should This Shape Healthcare Education?

Is It Time to Revamp the Drug Development Pipeline?

Video TranscriptExpand ↓

Although the COVID 19 vaccine is here isn't necessarily available for everyone, some countries across the globe do not have access to the singular thing that could end the pandemic due in part because of intellectual properties. Right now, there's a battle over whether or not countries like the United States should share the IP of the vaccine. We reached out to Dr. Kishore wassan about this topic, and we asked, is the WTO and the trips council right for lean so heavily on protecting IPS rather than what some may argue is looking out for the global good? On one level, I think scientifically and medically, we all in a humanitarian effort believe try to make the vaccines accessible and cost effective. So that people in the world can definitely get the vaccine so they could be taken care of. I mean, it's that simple. However, the reason why intellectual property is a really tricky situation is because unfortunately, you have rogue rogue organizations, rogue scientists, rogue people out there that if they try to do a knock off on your vaccine and develop something that is substandard and based on, maybe you're, you know, off your intellectual property and then try to push that to the developing world. So a substandard vaccine for the developing world that could actually be dangerous because that vaccine may be more toxic and not as effective because it's done substandard. So intellectual property is partly there because yes, it's there so they can make money and protect their invention. But at the same time, it's also there so that, you know, the product is protected. So that people don't do do rogue products and make a substandard version of it. That's why this isn't actually a very controversial and tricky issue. It's not that black and white. I mean, it's not as simple as that. So you have to kind of keep those two things in mind. And again, it comes down to a balance between the two, ok? You know, it really is something that you have to unfortunately have to think about. Dr. Watson is the co-founder and co-director of the neglected global disease initiative at the University of British Columbia, which strives for global equity and accessibility. He is supporter of life saving drugs that aren't just a COVID 19 vaccine not being made for profit, but he believes ultimately the biggest challenge when it comes to certain parts of the globe is them not being able to actually store the vaccine once it's delivered to them. I have to wear my other hat for this, so I am the co-founder and co-director of the neglected global diseases initiative at the University of British Columbia, and global equity and accessibility is one of our mandates of need. UBC and in fact, we're going to hold a hold a conference at the end of November to talk about global equity. And so on. And within that. Yes your comments around trips and accessibility of the vaccine at or below cost for the developing world is one of the things that Nagai supports and believes in. In fact, we believe that for four drugs, for neglected diseases, it's not just for COVID. We believe that there should be drugs or other what we call neglected diseases for the developing world that should be developed at or below cost. You know, you know, there may be cost recovery because it costs money to make it, but we're not. Certainly we don't believe that they should be making profit in those parts of the world. That is definitely one of the issues around vaccine and vaccine development in the developing and the developing world. But one of the bigger issues before that is accessibility. Being able to get the vaccine, being able to store the vaccine, be able to have proper storage facilities in many parts of the world. They do not have proper refrigeration, so they cannot store the vaccines properly in there. Therefore, how can you get them to be accessible? So these are some of the definite issues that are on the table that the world needs to deal with. And yeah, Nagai UBC is certainly an advocate for that. As long as COVID 19 is still around a debate for the ipa, the vaccine will continue to rage on for the latest on the vaccine and the factors that go with this distribution. Be sure to head the market scale as well as subscribe.

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Book DemoSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Healthcare Insights

How Memorial Hermann measured $37,500 in AI scribe value per ER doctor

How Memorial Hermann measured $37,500 in AI scribe value per ER doctor

Memorial Hermann emergency physicians using Ambience Healthcare's AI documentation generated about $37,500 more in yearly productivity value than non-users. That figure is gross and comparative. It comes from billing data annualized over 160 shifts and excludes software costs, so buyers must build the cost side themselves.

  • 01Memorial Hermann's $37,500 per emergency physician is gross: the gap in work RVUs per clinical hour between AI documentation users and non-users, annualized over 160 ten-hour shifts, before any software or implementation cost.
  • 02Divided out, that gain comes to roughly $234 a shift or about $23 per clinical hour, a practical yardstick to hold against any all-in per-physician cost quote.
  • 03When a vendor puts fees at risk against outcomes, the comparison group, billing source and acuity adjustment become contract terms, because they decide what counts as a gain worth paying for.

Nov 21, 2026

Capsa's RoboPharma HV Wall is the first central fill system confirmed compatible with Parcel Health's paper vials

Capsa's RoboPharma HV Wall is the first central fill system confirmed compatible with Parcel Health's paper vials

Capsa Healthcare says its RoboPharma HV Wall is the first central fill automation system confirmed to fill Parcel Health’s Tully Tube, a paper prescription vial. The confirmation matters because central fill and mail order sites can only use containers their machines can handle—but this applies to the HV Wall specifically and is not a named production deployment. Buyers can see the vials at ASHP Midyear, Dec. 6–9.

  • 01A central fill site can't switch to a paper vial its automation can't handle. Confirmed machine compatibility is the gate, and the RoboPharma HV Wall is the first system through it for the Tully Tube.
  • 02The up to 71 percent plastic reduction per unit is a ceiling measured against a similar-size plastic vial, so operators modeling sustainability targets should ask for the comparison basis for their own vial sizes.

Nov 20, 2026

Luminopia's CEO says payer churn slows coverage and can require patching first

Luminopia's CEO says payer churn slows coverage and can require patching first

Luminopia co-founder and CEO Scott Xiao told HLTH's Partner Highlight series that short payer member tenure and a fragmented Medicaid leave pediatric amblyopia neglected. A 2025 JMCP payer roundtable recommended covering the FDA-authorized therapy but allowed step-edits, while PEDIG data show two-hour patching adds about 1.1 lines of acuity. Cleveland Clinic registry data report 1.8 lines of gain in severe cases.

  • 01A 2025 payer roundtable in the Journal of Managed Care & Specialty Pharmacy recommended plans cover Luminopia, yet said step-edits and letters of exception may still be required, with more than 9,000 prescriptions written since November 2022.
  • 02PEDIG's ATS05 trial put two hours of daily patching at 1.1 lines of gain over five weeks versus 0.5 lines for glasses alone, while a 2015 AAO review tied patching's poor compliance to social stigma.
  • 03S.1702, the Access to Prescription Digital Therapeutics Act of 2025, has sat in the Senate Finance Committee since May 8, 2025, leaving coverage negotiated plan by plan.

Nov 19, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512